Please login to the form below
Shionogi
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Shionogi's 2012 Japan sales performance.
ViiV and Janssen plan pivotal trials of monthly HIV treatment
ViiV- a joint venture between GlaxoSmithKline, Pfizer and Shionogi - said that while HIV can be considered a manageable condition with access to modern drugs, there are still a number of areas
ViiV agrees $1.5bn deal to acquire BMS' HIV assets
ViiV is a joint venture between GlaxoSmithKline, Pfizer and Shionogi and is currently the second-biggest player in HIV therapies after Gilead Sciences with a market share of around 20%, well
HIV deal in China helps GSK rebuild tattered reputation
GSK had intended to spin out ViiV - a joint venture with Pfizer and Shionogi in which the company has an 80% stake - but backtracked in May given the unit's growth
GSK shelves ViiV sale as it lays out growth strategy
Shares in the company traded up in the decision to hang onto ViiV - partnered with Pfizer and Shionogi but with GSK owning an 80% stake - as well as bullish statements from
ViiV maintains top spot in reputation survey
Shionogi came out top.
[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Subscribe to our email news alerts
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- MHRA to introduce new UK clinical trials framework
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Janssen’s single tablet combination shows promise in phase 3 PAH study
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- How to make sure your adverts for clinical trials are compliant
PMHub
Wisepress
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
